Discover and read the best of Twitter Threads about #REMAP

Most recents (2)

#ACTION RCT results just published @TheLancet: Another negative study of therapeutic #anticoagulantion (TA) in hospitalized people w/ COVID19:
- TA w/ rivaroxaban didn’t improve survival (or *any* endpoint) vs prophylaxis
- more bleeding with TA
1/
thelancet.com/journals/lance…
The AntiCoagulaTlon cOroNavirus (ACTION) trial was a pragmatic open label RCT at 31 hospitals in 🇧🇷.

It enrolled hospitalized patients with COVID19 & an elevated D-dimer & randomized to TA vs prophylactic anticoagulation (PA).

Aside: not sure how I feel about that acronym...
2/
The intervention was TA with either a DOAC (rivaroxaban) if stable or LMWH (enoxaparin 1mg/kg BID) if unstable vs standard of care prophylaxis (UFH or LMWH).

Crossovers were allowed (eg if someone in the PA developed VTE). They adjusted dosing for renal function.

3/
Read 12 tweets
Have you registered for the upcoming CSRC meeting? Join me & others from academia, industry, & regulatory agencies for a follow-up #CardiogenicShock Think Tank on July 24! Register here: bit.ly/2PtxKoE @CardiacSafety
For my part, I'll be talking about the possibility of Randomized, Embedded, Multifactorial, Adaptive, Platform trials and whether they could be a useful tool in generating evidence for the treatment of cardiogenic shock.
This is especially timely in light of the news that the critical care world has just launched the first #REMAP trial in the US:

Read 3 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!